安旭生物
(688075)
| 流通市值：47.01亿 | | | 总市值：47.01亿 |
| 流通股本：1.27亿 | | | 总股本：1.27亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 71,198,925.07 | 451,255,115.98 | 325,286,887.42 | 229,747,240.9 |
| 营业收入 | 71,198,925.07 | 451,255,115.98 | 325,286,887.42 | 229,747,240.9 |
| 二、营业总成本 | 120,853,303.06 | 531,110,941.6 | 392,903,928.66 | 257,664,669.31 |
| 营业成本 | 42,150,052.81 | 259,452,157.82 | 192,489,887.23 | 139,893,380.26 |
| 税金及附加 | 2,000,985.64 | 28,330,572.04 | 31,360,037.43 | 10,320,644.81 |
| 销售费用 | 9,238,485.19 | 52,541,619.57 | 39,442,184.06 | 27,195,877.65 |
| 管理费用 | 13,097,238.57 | 54,639,411.83 | 38,137,945.52 | 22,987,458.38 |
| 研发费用 | 15,851,993.7 | 78,650,057.24 | 63,702,440.14 | 47,409,960.28 |
| 财务费用 | 38,514,547.15 | 57,497,123.1 | 27,771,434.28 | 9,857,347.94 |
| 其中:利息费用 | - | 275,568.31 | - | 1,004.27 |
| 其中:利息收入 | -905,770.88 | 2,684,087.83 | -1,834,015.85 | -1,112,596.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,842,223.36 | 26,572,894.84 | 32,452,856.8 | 22,444,815.69 |
| 加:投资收益 | 23,299,039.11 | 128,208,684.84 | 89,864,833.01 | 59,702,962.11 |
| 资产处置收益 | - | 66,315.36 | 130,444.56 | 131,398.95 |
| 资产减值损失(新) | - | -8,121,508.05 | - | - |
| 信用减值损失(新) | 67,464.98 | -4,359,176.93 | -1,673,669.58 | -1,673,669.58 |
| 其他收益 | 4,278,874.09 | 7,060,291.49 | 5,594,830.22 | 4,131,873.2 |
| 营业利润平衡项目 | 0 | 0 | 0.01 | 0 |
| 四、营业利润 | -14,166,776.45 | 69,571,675.93 | 58,752,253.78 | 56,819,951.96 |
| 加:营业外收入 | 28,496.99 | 6,635,466.37 | 5,528,902.88 | 4,707,679.88 |
| 减:营业外支出 | 4,329.17 | 1,333,956.81 | 44,443.35 | 36,770.76 |
| 五、利润总额 | -14,142,608.63 | 74,873,185.49 | 64,236,713.31 | 61,490,861.08 |
| 减:所得税费用 | -3,788,397.52 | 5,663,414.18 | -71,352 | 2,306,148.84 |
| 六、净利润 | -10,354,211.11 | 69,209,771.31 | 64,308,065.31 | 59,184,712.24 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -10,354,211.11 | 69,209,771.31 | 64,308,065.31 | 59,184,712.24 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -10,360,017.27 | 69,421,291.74 | 64,358,593.74 | 59,305,890.78 |
| 少数股东损益 | 5,806.16 | -211,520.43 | -50,528.43 | -121,178.54 |
| 扣除非经常损益后的净利润 | -20,383,937.46 | 13,899,688.47 | 17,639,112.61 | 23,586,168.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.08 | 0.55 | 0.51 | 0.47 |
| (二)稀释每股收益 | -0.08 | 0.55 | 0.51 | 0.47 |
| 八、其他综合收益 | -3,750,019.69 | -6,747,745.4 | -3,687,365.57 | -2,142,147.47 |
| 归属于母公司股东的其他综合收益 | -3,750,019.69 | -6,747,745.4 | -3,687,365.57 | -2,142,147.47 |
| 九、综合收益总额 | -14,104,230.8 | 62,462,025.91 | 60,620,699.74 | 57,042,564.77 |
| 归属于母公司股东的综合收益总额 | -14,110,036.96 | 62,673,546.34 | 60,671,228.17 | 57,163,743.31 |
| 归属于少数股东的综合收益总额 | 5,806.16 | -211,520.43 | -50,528.43 | -121,178.54 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |